Endpoints NewsUpdated: Biogen sells just $300K worth of Aduhelm in Q3, as questions on long-term viability remainOct 20, 2021more_vert
The New York TimesSales of Biogen's Alzheimer's Drug Fall Short of ExpectationsOct 20, 2021Rebecca RobbinsBy Rebecca Robbinsmore_vert